SHAREHOLDER Alert: Rigrodsky Regulation, P.A. Announces Investigation of Obalon Therapeutics, Inc. Merger

The MarketWatch News Department was not concerned in the generation of this articles.

WILMINGTON, Del., Jan 25, 2021 (Globe NEWSWIRE by way of COMTEX) —
WILMINGTON, Del., Jan. 25, 2021 (World NEWSWIRE) — Rigrodsky Legislation, P.A. announces that it is investigating Obalon Therapeutics, Inc. (“Obalon”) (NASDAQ GS: OBLN) about doable breaches of fiduciary responsibilities and other violations of regulation associated to Obalon’s agreement to merge with ReShape Lifesciences, Inc.

To learn a lot more about this investigation and your rights, stop by: https://www.rl-lawful.com/scenarios-obalon-therapeutics-inc.

You might also contact Seth D. Rigrodsky or Gina M. Serra value and obligation cost-free at (888) 969-4242 or [email protected].

Rigrodsky Legislation, P.A., with offices in Delaware and New York, has recovered hundreds of hundreds of thousands of pounds on behalf of traders and realized sizeable corporate governance reforms in securities fraud and company class actions nationwide.

Lawyer promotion. Prior effects do not promise a comparable end result.

Get in touch with:

Rigrodsky Regulation, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Cost-free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-lawful.com

COMTEX_379458933/2471/2021-01-25T11:30:35

Is there a difficulty with this press release? Contact the source service provider Comtex at [email protected] You can also call MarketWatch Buyer Service by way of our Customer Heart.

(C) Copyright 2021 GlobeNewswire, Inc. All legal rights reserved.

The MarketWatch News Section was not concerned in the development of this articles.

About Megan B. Schulze

Check Also

A Continued Lack of ‘Grace’ in Lawful Malpractice

Andrew Lavoott Bluestone In 2014 we wrote about a new and unparalleled rule that if an charm of the case primary to a authorized malpractice motion was moderately most likely to succeed, that attractiveness have to be taken or the authorized malpractice scenario is waived. Grace v. Law, 24 N.Y.3d 203 (2014). This rule sprang …